Total Payments
$745,823
2024 Payments
$39,864
Companies
29
Transactions
341
Medicare Patients
13,668
Medicare Billing
$3.1M
Payment Breakdown by Category
Research$442,798 (59.4%)
Consulting$246,972 (33.1%)
Other$39,796 (5.3%)
Travel$10,998 (1.5%)
Food & Beverage$4,816 (0.6%)
Education$444.14 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $442,798 | 44 | 59.4% |
| Consulting Fee | $246,972 | 135 | 33.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,796 | 38 | 4.9% |
| Travel and Lodging | $10,998 | 29 | 1.5% |
| Food and Beverage | $4,816 | 85 | 0.6% |
| Honoraria | $3,000 | 2 | 0.4% |
| Education | $444.14 | 8 | 0.1% |
Payments by Type
Research
$442,798
44 transactions
General
$303,025
297 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $403,120 | 33 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $62,851 | 44 | $0 (2024) |
| F. Hoffmann-La Roche AG | $60,763 | 52 | $0 (2024) |
| ABBVIE INC. | $34,412 | 51 | $0 (2024) |
| Genentech, Inc. | $25,562 | 17 | $0 (2024) |
| PFIZER INC. | $20,190 | 12 | $0 (2021) |
| Acerta Pharma LLC | $19,913 | 3 | $0 (2019) |
| Eli Lilly and Company | $16,174 | 12 | $0 (2024) |
| BeiGene USA, Inc. | $13,515 | 11 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $13,295 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,864 | 44 | F. Hoffmann-La Roche AG ($13,879) |
| 2023 | $18,196 | 32 | E.R. Squibb & Sons, L.L.C. ($5,892) |
| 2022 | $33,647 | 24 | Genentech, Inc. ($6,584) |
| 2021 | $68,642 | 37 | AstraZeneca Pharmaceuticals LP ($23,255) |
| 2020 | $64,810 | 29 | F. Hoffmann-La Roche AG ($24,739) |
| 2019 | $108,160 | 55 | Celgene Corporation ($53,851) |
| 2018 | $195,826 | 63 | Celgene Corporation ($157,263) |
| 2017 | $216,678 | 57 | Celgene Corporation ($187,967) |
All Payment Transactions
341 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $3,181.45 | Research |
| Study: MorningSun | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $3,181.45 | Research |
| Study: MorningSun | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | Venclexta (Biological) | — | In-kind items and services | $1,439.75 | Research |
| Study: CLL 1L Fit GV FCR BR • Category: BioOncology | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | Venclexta (Biological) | — | In-kind items and services | $1,283.75 | Research |
| Study: CLL 1L Fit GV FCR BR • Category: BioOncology | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $652.34 | Research |
| Study: Polarix | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | Venclexta (Biological) | — | In-kind items and services | $487.25 | Research |
| Study: CLL 1L Fit GV FCR BR • Category: BioOncology | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | Venclexta (Biological) | — | In-kind items and services | $487.25 | Research |
| Study: CLL 1L Fit GV FCR BR • Category: BioOncology | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $59.88 | Research |
| Study: Polarix | ||||||
| 12/18/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Eli Lilly and Company | JAYPIRCA (Drug) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $113.14 | General |
| Category: Oncology | ||||||
| 12/07/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $118.88 | General |
| Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Janssen Global Services, LLC | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $125.03 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Janssen Global Services, LLC | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $29.25 | General |
| Category: BioOncology | ||||||
| 11/22/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Oncology | ||||||
| 11/06/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 10/18/2024 | Janssen Global Services, LLC | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,635.00 | General |
| Category: Oncology | ||||||
| 10/15/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,565.00 | General |
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,671.85 | Research |
| Study: Polarix | ||||||
| 08/26/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| 08/23/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Oncology | ||||||
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-5013-NHL-008 | Celgene Corporation | $174,565 | 2 |
| CC-5013-NHL-008 - A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicu | Celgene Corporation | $149,493 | 2 |
| A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) | Celgene Corporation | $44,969 | 2 |
| A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia | Acerta Pharma LLC | $18,663 | 2 |
| A REVIEW OF THE EVIDENCE ON EFFECTIVENESS OF DEBULKING STRATEGIES IN REDUCING TUMOR LYSIS SYNDROME RISK IN VENETOCLAX-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | F. Hoffmann-La Roche AG | $12,754 | 1 |
| MorningSun | F. Hoffmann-La Roche AG | $7,690 | 4 |
| Antibody-drug conjugates for previously treated aggressive lymphomas focus on polatuzumab vedotin | F. Hoffmann-La Roche AG | $6,193 | 1 |
| CC-5013-CLL-010 | Celgene Corporation | $4,267 | 1 |
| Gazyva GA101 Plus Benda CLL | F. Hoffmann-La Roche AG | $3,909 | 2 |
| CLL 1L Fit GV FCR BR | F. Hoffmann-La Roche AG | $3,698 | 4 |
| PCYC-1134M-CA | Pharmacyclics LLC, An AbbVie Company | $3,001 | 5 |
| Polarix | F. Hoffmann-La Roche AG | $2,998 | 6 |
| Celgene - Connect CLL | Celgene Corporation | $2,533 | 1 |
| A PHASE IBII STUDY EVALUATING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH EITHER OBINUTUZUMAB PLUS BENDAMUSTINE OR OBINUTUZUMAB PLUS CHOP IN PATIENTS WITH FOLLICULAR LYMPHOMA OR RITUXIMAB PLUS CHOP IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA | F. Hoffmann-La Roche AG | $2,026 | 1 |
| AG-221-AML-004 | Celgene Corporation | $1,463 | 1 |
| A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | ABBVIE INC. | $1,382 | 3 |
| An Open-Label Study of Obinutuzumab GA101 Plus Bendamustine in Patients with Previously Untreated Chronic Lymphocytic Leukemia | F. Hoffmann-La Roche AG | $1,082 | 1 |
| Moving beyond cell of origin subtypes in POLARIX towards molecular profiling of DLBCL for precision medicine | F. Hoffmann-La Roche AG | $820.51 | 1 |
| A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSEDREFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 ABT-199 PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB | F. Hoffmann-La Roche AG | $801.00 | 2 |
| A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma (CC-5013-NHL-007) | Celgene Corporation | $476.00 | 1 |
| UTXTGR205 | TG Therapeutics, Inc. | $15.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 53 | 3,194 | 47,713 | $4.4M | $878,633 |
| 2022 | 58 | 3,183 | 71,311 | $4.7M | $1.0M |
| 2021 | 57 | 3,668 | 65,449 | $3.3M | $669,689 |
| 2020 | 61 | 3,623 | 59,351 | $3.3M | $562,543 |
Total Patients
13,668
Total Services
243,824
Medicare Billing
$3.1M
Procedure Codes
229
All Medicare Procedures & Services
229 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 11 | 9,180 | $1.2M | $346,792 | 27.9% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 15 | 4,000 | $586,200 | $173,510 | 29.6% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 18 | 3,369 | $845,218 | $113,286 | 13.4% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 14 | 1,943 | $376,360 | $43,746 | 11.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 285 | 684 | $159,852 | $42,410 | 26.5% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 17 | 14,125 | $296,625 | $33,452 | 11.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 104 | 188 | $128,968 | $18,450 | 14.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 82 | 139 | $45,975 | $12,711 | 27.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 366 | 985 | $61,070 | $10,119 | 16.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 369 | 1,009 | $19,171 | $8,404 | 43.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 374 | 1,049 | $36,715 | $7,927 | 21.6% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 26 | 5,720 | $51,480 | $7,662 | 14.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 24 | 114 | $26,790 | $6,272 | 23.4% |
| 83520 | Measurement of substance using immunoassay technique | Office | 2023 | 65 | 358 | $64,798 | $6,059 | 9.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 43 | 93 | $20,181 | $5,702 | 28.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 48 | 114 | $34,656 | $5,271 | 15.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 35 | 35 | $17,815 | $4,041 | 22.7% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 273 | 663 | $19,890 | $3,880 | 19.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 41 | 57 | $13,281 | $3,802 | 28.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 77 | 283 | $29,715 | $3,239 | 10.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 11 | 13 | $13,468 | $2,341 | 17.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 28 | 90 | $14,040 | $1,926 | 13.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 39 | 86 | $13,072 | $1,813 | 13.9% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 18 | 101 | $9,797 | $1,550 | 15.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 23 | 32 | $10,688 | $1,547 | 14.5% |
About Dr. Jeff Sharman, M.D
Dr. Jeff Sharman, M.D is a Hematology & Oncology healthcare provider based in Eugene, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/17/2007. The National Provider Identifier (NPI) number assigned to this provider is 1659596179.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeff Sharman, M.D has received a total of $745,823 in payments from pharmaceutical and medical device companies, with $39,864 received in 2024. These payments were reported across 341 transactions from 29 companies. The most common payment nature is "" ($442,798).
As a Medicare-enrolled provider, Sharman has provided services to 13,668 Medicare beneficiaries, totaling 243,824 services with total Medicare billing of $3.1M. Data is available for 4 years (2020–2023), covering 229 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Eugene, OR
- Active Since 04/17/2007
- Last Updated 08/05/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1659596179
Products in Payments
- Revlimid (Drug) $382,827
- CALQUENCE (Drug) $83,033
- BRUKINSA (Drug) $16,602
- VENCLEXTA (Biological) $16,016
- Venclexta (Drug) $15,850
- GAZYVA (Biological) $15,285
- JCAR017 (Drug) $10,203
- VENCLEXTA (Drug) $9,800
- POLIVY (Biological) $7,843
- IMBRUVICA (Drug) $6,706
- Non-Covered Product (Drug) $6,580
- Aliqopa (Drug) $6,100
- UKONIQ (Drug) $6,091
- Imbruvica (Drug) $5,944
- Gazyva (Biological) $4,991
- Zydelig (Drug) $4,725
- EPKINLY (Drug) $4,553
- Venclexta (Biological) $4,499
- JAYPIRCA (Drug) $3,825
- Ibrutinib (Drug) $3,001
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Eugene
Dr. Christopher Yasenchak, M.d, M.D
Hematology & Oncology — Payments: $114,099
Hematology & Oncology $114,099
James Butrynski, M.d, M.D
Hematology & Oncology — Payments: $22,425
Hematology & Oncology $22,425
Dr. Glenn Buchanan, Md, MD
Hematology & Oncology — Payments: $1,992
Hematology & Oncology $1,992
Dr. Jae Lee, Md, MD
Hematology & Oncology — Payments: $358.03
Hematology & Oncology $358.03
Dr. Barry Mckenzie, Md, MD
Hematology & Oncology — Payments: $281.16
Hematology & Oncology $281.16
Dr. James Fitzgibbons, Md, MD
Hematology & Oncology — Payments: $103.41
Hematology & Oncology $103.41